US EditionAnne Wojcicki’s Nonprofit Wins Bid to Acquire Genetic Testing Company 23andMe
- TTAM Research Institute, led by Anne Wojcicki, announced its acquisition of nearly all of 23andMe's assets for $305 million, surpassing Regeneron's offer of $256 million.
- The acquisition includes 23andMe's core genetic testing business, research services, and telehealth subsidiary, Lemonaid Health.
- Anne Wojcicki, co-founder of 23andMe, expressed her excitement about continuing the company's mission, stating, "I am thrilled that TTAM Research Institute will be able to continue the mission of 23andMe."
- The deal is contingent upon approval from the U.S. Bankruptcy Court for the Eastern District of Missouri.
29 Articles
29 Articles
Anne Wojcicki buys back 23andMe in $305M deal, outbids Regeneron - Tech Startups
Less than three months after Regeneron said it would acquire 23andMe’s assets for $256 million, Anne Wojcicki has taken back control of the troubled DNA testing company she co-founded. On Friday, Wojcicki’s new nonprofit, TTAM Research Institute, announced it would […] The post Anne Wojcicki buys back 23andMe in $305M deal, outbids Regeneron first appeared on Tech Startups.
New York, 13 Jun (EFE).- U.S. businesswoman Susan Wojcicki, one of the creators of the broken genetic testing company 23andMe, regained control this Friday by making a bid of 305 million dollars that surpassed the one recently announced by a biotech firm. Wojcicki, who is also the former deputy advisor of 23andMe, entered today into a “final round of bids” in the post-compulsory auction process with the biotechnology company Regeneron, which in …
Founder’s Nonprofit TTAM to Acquire 23andMe in Surprise Turnaround – RamaOnHealthcare
Anne Wojcicki, co-founder and former CEO of direct-to-consumer genetic testing company 23andMe, has succeeded in a bid to buy almost all the assets of the bankrupt company through a nonprofit set up by Wojcicki in May this year called TTAM.TTAM has undeclared backers in industry, and according to its website “is a nonprofit medical research [...]
Coverage Details
Bias Distribution
- 67% of the sources are Center
To view factuality data please Upgrade to Premium
